Novo Nordisk A/S (NYSE:NVO) Shares Sold by Private Advisor Group LLC

Private Advisor Group LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 16.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 77,840 shares of the company’s stock after selling 15,223 shares during the quarter. Private Advisor Group LLC’s holdings in Novo Nordisk A/S were worth $6,696,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Natixis Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares in the last quarter. Versant Capital Management Inc acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $86,000. Talbot Financial LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $4,066,000. Finally, Clear Creek Financial Management LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $450,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Up 5.2 %

NVO opened at $88.07 on Friday. The stock has a market capitalization of $395.19 billion, a PE ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $77.82 and a 12-month high of $148.15. The firm’s fifty day moving average price is $86.01 and its 200 day moving average price is $108.22. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.